ArticleCureus2025
Prevalence and Characteristics of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Complications in Patients With Biliopancreatic Disorders: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the prevalence and clinical characteristics of post-endoscopic retrograde cholangiopancreatography (ERCP) complications, particularly acute pancreatitis, in patients with biliopancreatic disorders treated at a secondary-level referral hospital in Mexico between April 1, 2020, and December 31, 2023, and to compare outcomes between patients who received biliary stents and those who did not. MATERIALS AND
methodsThis was an observational and retrospective study conducted at a secondary-level hospital in Mexico. A total of 151 medical records of patients who underwent ERCP were reviewed. Variables included sex, age, hyperamylasemia, hyperlipasemia, acute post-ERCP pancreatitis, and related complications.
resultsThe study included 151 patients, with a median age of 51 years and a predominance of female patients (60%, n = 90). Biliary stents were placed in 66% (n = 100), while 34% (n = 51) did not receive a stent. The most common indications for ERCP were choledocholithiasis (76%, n = 115), biliary stricture (11%, n = 16), suspected biliary tumor (4%, n = 6), and other causes (9%, n = 14). Post-ERCP pancreatitis, defined as abdominal pain following the procedure accompanied by elevated lipase and amylase levels, occurred in 4% (n = 4) of patients without a stent and 3.9% (n = 2) with a stent. Isolated hyperlipasemia and hyperamylasemia without clinical pancreatitis occurred in 11% (n = 17) and 8.6% (n = 13) of patients, respectively. Significant differences were observed in ERCP indications between groups: choledocholithiasis was more frequent in the non-stent group (90%, n = 90 of 100) compared to the stent group (49%, n = 25 of 51), whereas biliary strictures (25%, n = 13 of 51 vs. 3%, n = 3 of 100) and unresolved stones (80%, n = 41 of 51 vs. 25%, n = 25 of 100) were more common in the stented group (all p < 0.001).
conclusionThe prevalence of post-ERCP pancreatitis was consistent with that reported in the international literature, with a higher incidence in women. ERCP continues to play a key role in the management of biliopancreatic diseases, underscoring the importance of ongoing research to enhance comprehensive care for the Mexican population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.